The The Digital Doc: Exploring Health Tech Innovation

DEA Extends Telemedicine Flexibilities for Prescribing of Controlled Medications

Drug Enforcement Administration (DEA) released a second temporary rule extending the COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications

Nathan A. Beaver and Thomas B. Ferrante of Foley & Lardner LLP-Health Care Law Today

Email Dr. Erkeda for consulting & friendly PC partnerships @ [email protected]

Here are the details:

DEA's Second Temporary Rule on COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications

  • Overview:

    • On October 6, 2023, DEA announced a second temporary rule extending COVID-19 telemedicine flexibilities.

    • Without this extension, the flexibilities would expire on November 11, 2023 for newly established practitioner-patient relationships.

    • Flexibilities initially introduced in March 2020 are now extended until December 31, 2024.

  • Key Provisions:

    1. Scope of DEA waivers under this rule:

      • Extends the "full set" of telemedicine flexibilities for prescription of controlled medications.

      • Refers to two DEA letters from March 2020, detailing:

        • Waivers on DEA registrations in individual states.

        • Waivers on in-person evaluation requirements for online prescriptions.

        • Flexibility to prescribe buprenorphine to patients with opioid use disorder via telephone without an in-person exam.

      • Foley confirmed with DEA's Scott Brinks that the single-state DEA registration policy from the March 25, 2020 letter is extended.

    2. Time Period of the Second Temporary Rule:

      • Flexibilities extended through December 31, 2024.

      • Removed distinction between new and previously seen patients in the initial extension. All DEA-registered practitioners can now prescribe schedule II-V controlled medications via telemedicine through the end of 2024.

    3. Future DEA Rulemaking:

      • DEA plans to introduce new standards by the Fall of 2024.

      • Indicates a possible need for a third extension before new rules come into effect.

  • Conclusion:

    • Extension benefits telemedicine companies, allowing them to plan until the end of 2024.

    • It's uncertain what the DEA's 2024 proposal will entail regarding special telemedicine registration.

    • Ongoing monitoring is recommended for further updates.

How can Dr. Erkeda help your team:

  • Available to serve as healthcare tech consultant- specializes in workflow optimization, strategy, tech optimization, health equity integration, and more

  • Available to provide workshops and talks on leadership, overcoming obstacles, telehealth, and healthtech

  • Licensed in 48 states and DC with extensive leadership experience in telehealth- Able to serve as Friendly PC owner for startups

  • Email [email protected] with inquiries

Dr Erkeda also hosts leadership and telehealth workshops/ lunch & learns